References
- Wong C. S. M., Strange R. C., Lear J. T. Basal cell carcinoma. Br Med J 2003; 327: 794–8
- Marks R., Gebauer K., Shumack S., Amies M., Bryden J., Fox T. L., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6‐week dose–response trial. J Am Acad Dermatol 2001; 44: 807–13
- Schulze H. J., Cribier B., Requena L., Reifenberger J., Ferrandiz C., Diez A. G., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle‐controlled phase III study in Europe. Br J Dermatol 2005; 152: 939–47
- Geisse J., Caro I., Lindholm J., Golitz L., Stampone P., Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle‐controlled studies. J Am Acad Dermatol 2004; 50: 722–33
- Vidal D., Matias‐Guiu X., Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004; 29: 518–25
- Stockfleth E., Trefzer U., Garcia‐Bartels C., Wegner T., Schmook T., Sterry W. The use of Toll‐like receptor‐7 agonist in the treatment of basal cell carcinoma: An overview. Br J Dermatol 2003; 149: 53–6
- Testerman T. L., Gerster J. F., Imbertson L. M., Reiter M. J., Miller R. L., Gibson S. J., et al. Cytokine induction by the immunomodulators imiquimod and S‐27609. J Leukoc Biol 1995; 58: 365–72
- Beutner K. R., Geisse J. K., Helman D., Fox T. L., Ginkel A., Owens M. L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002–7
- Sterry W., Ruzicka T., Herrera E., Takwale A., Bichel J., Andres K., et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low‐frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227–36
- Gollnick H., Barona C. G., Frank R. G. J., Ruzicka T., Megahed M., Tebbs V., et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: Interim 2‐year results from an ongoing 5‐year follow‐up study in Europe. Eur J Dermatol 2005; 15: 374–81